The tumor types we’re focused on are lung, breast and malignant heme. We also have a strong emphasis on colorectal cancer, because there have been more and more cases of earlier diagnosed colorectal ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own ...
EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic ...
London, UK – May 05, 2026. Cytospire Therapeutics (‘Cytospire’), a UK based biotech developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results